Skip to main content

Table 1 Baseline characteristics

From: Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: The Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry

  Total (n = 1143) PP (−) (n = 260) PP (+) (n = 883) P
Age, years 60.7 ± 9.3 58.7 ± 9.6 61.3 ± 9.1 < 0.001
Male, n (%) 624 (54.6) 122 (46.9) 502 (56.9) 0.005
Systolic BP, mmHg 126.1 ± 16.6 123.7 ± 16.3 126.8 ± 16.6 0.011
Diastolic BP, mmHg 77.0 ± 10.6 75.9 ± 11.1 77.3 ± 10.5 0.079
BMI, kg/m2 24.8 ± 3.0 24.3 ± 3.0 25.0 ± 3.0 0.002
BMI ≥ 25.0 kg/m2, n (%) 493 (43.9) 97 (37.5) 396 (45.8) 0.017
Hypertension, n (%) 674 (59.0) 123 (47.3) 551 (62.5) < 0.001
Diabetes, n (%) 319 (27.9) 48 (18.5) 271 (30.7) < 0.001
Hyperlipidemia, n (%) 381 (33.3) 69 (26.5) 312 (35.4) 0.008
Current smoking, n (%) 213 (18.6) 42 (16.2) 171 (19.4) 0.239
Medications, n (%)
 Aspirin 555 (48.6) 107 (41.2) 448 (50.8) 0.006
 Beta blocker 353 (31.0) 81 (31.2) 272 (30.9) 0.940
 ACEI/ARB 389 (34.2) 67 (25.9) 332 (36.6) 0.001
 Statin 520 (45.5) 89 (34.2) 431 (49.5) < 0.001
 Insulin therapy 33 (2.9) 5 (2.0) 28 (3.2) 0.294
 Total cholesterol, mg/dL 182.6 ± 38.4 184.4 ± 39.6 182.0 ± 38.1 0.393
 Triglyceride, mg/dL 143.3 ± 83.1 132.8 ± 73.9 146.4 ± 85.4 0.020
 HDL-C, mg/dL 48.7 ± 12.3 50.3 ± 12.8 48.2 ± 12.1 0.016
 LDL-C, mg/dL 111.5 ± 34.1 113.5 ± 34.2 110.9 ± 34.0 0.289
 Creatinine, mg/dL 1.01 ± 0.67 0.96 ± 0.47 1.01 ± 0.72 0.233
 FBG, mg/dL 110.7 ± 35.0 104.2 ± 28.6 112.7 ± 36.5 < 0.001
 HbA1c, % 6.46 ± 1.27 6.26 ± 1.19 6.51 ± 1.28 0.067
 TyG index 8.81 ± 0.59 8.69 ± 0.55 8.85 ± 0.60 < 0.001
  1. Values are presented as mean ± standard deviation or number (%)
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, FBG fasting blood glucose, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TyG triglyceride glucose